Insights

Innovative Monitoring Tech Rhaeos has developed FlowSense, a noninvasive wireless skin patch that can assess cerebrospinal fluid flow in hydrocephalus patients, presenting a new standard for bedside monitoring and potential expansion into other fluid flow assessments.

Strong Funding Momentum With over 19 million dollars in total financing, including recent Series A investment and NIH grants, Rhaeos demonstrates solid investor confidence and a robust financial foundation to support product launch and market growth activities.

Market Readiness The company is on track for initial market entry in 2024, indicating readiness to engage hospitals and healthcare providers for early adoption of FlowSense, unlocking initial sales opportunities within neurocritical care settings.

Leadership Expansion The recent appointment of a Chief Medical Officer signals a focus on clinical validation and strategic partnerships, creating opportunities to collaborate on clinical studies and accelerate clinician adoption.

Regulatory Advantages Receiving FDA breakthrough designation highlights a favorable regulatory pathway, making it easier to navigate approval and accelerate commercialization efforts, opening doors for early sales relationships with key medical institutions.

Rhaeos Tech Stack

Rhaeos uses 8 technology products and services including Open Graph, Font Awesome, JSON-LD, and more. Explore Rhaeos's tech stack below.

  • Open Graph
    Content Management System
  • Font Awesome
    Font Scripts
  • JSON-LD
    Javascript Frameworks
  • Yoast SEO
    Search Engines
  • reCAPTCHA
    Security
  • MediaElement.js
    Video Players
  • Google Analytics
    Web Analytics
  • WP Fastest Cache
    Web Platform Extensions

Media & News

Rhaeos's Email Address Formats

Rhaeos uses at least 1 format(s):
Rhaeos Email FormatsExamplePercentage
FLast@rhaeos.comJDoe@rhaeos.com
43%
FirstLast@rhaeos.comJohnDoe@rhaeos.com
7%
FLast@rhaeos.comJDoe@rhaeos.com
43%
FirstLast@rhaeos.comJohnDoe@rhaeos.com
7%

Frequently Asked Questions

Where is Rhaeos's headquarters located?

Minus sign iconPlus sign icon
Rhaeos's main headquarters is located at 909 Davis Street Suite 500 Evanston, Illinois 60201 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Rhaeos's official website and social media links?

Minus sign iconPlus sign icon
Rhaeos's official website is rhaeos.com and has social profiles on LinkedInCrunchbase.

What is Rhaeos's NAICS code?

Minus sign iconPlus sign icon
Rhaeos's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Rhaeos have currently?

Minus sign iconPlus sign icon
As of March 2026, Rhaeos has approximately 23 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Co-Founder: S. K.Board Director & Chairman: C. S.Clinical Research Intern: N. E. J.. Explore Rhaeos's employee directory with LeadIQ.

What industry does Rhaeos belong to?

Minus sign iconPlus sign icon
Rhaeos operates in the Medical Equipment Manufacturing industry.

What technology does Rhaeos use?

Minus sign iconPlus sign icon
Rhaeos's tech stack includes Open GraphFont AwesomeJSON-LDYoast SEOreCAPTCHAMediaElement.jsGoogle AnalyticsWP Fastest Cache.

What is Rhaeos's email format?

Minus sign iconPlus sign icon
Rhaeos's email format typically follows the pattern of FLast@rhaeos.com. Find more Rhaeos email formats with LeadIQ.

How much funding has Rhaeos raised to date?

Minus sign iconPlus sign icon
As of March 2026, Rhaeos has raised $1.5M in funding. The last funding round occurred on Oct 09, 2023 for $1.5M.

When was Rhaeos founded?

Minus sign iconPlus sign icon
Rhaeos was founded in 2018.

Rhaeos

Medical Equipment ManufacturingIllinois, United States11-50 Employees

Rhaeos is a VC backed, clinical stage medical device company developing FlowSense, a platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now with FlowSense.

FlowSense, is a proprietary wireless, wearable, and noninvasive sensor that can be mounted on skin overlying the shunt to detect the presence and magnitude of CSF. Its miniaturized, thin construction is similar in size to a bandage, and it is composed primarily of soft, silicone rubber with no hard edges. Data is wirelessly transmitted to a custom designed mobile app. 

Rhaeos received FDA breakthrough designation for FlowSense, is NIH and NSF funded (>$7.5M), published clinical data in Science and Nature family journals, and is on track for initial market entry in 2024. To date, the company has brought in >$19M in dilutive and non-dilutive financing. Follow on products for other chronic conditions are currently in development.

Section iconCompany Overview

Headquarters
909 Davis Street Suite 500 Evanston, Illinois 60201 United States
Website
rhaeos.com
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $1.5M

    Rhaeos has raised a total of $1.5M of funding over 8 rounds. Their latest funding round was raised on Oct 09, 2023 in the amount of $1.5M.

  • $1M$10M

    Rhaeos's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1.5M

    Rhaeos has raised a total of $1.5M of funding over 8 rounds. Their latest funding round was raised on Oct 09, 2023 in the amount of $1.5M.

  • $1M$10M

    Rhaeos's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.